Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @VeristatCRO
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @VeristatCRO
-
Get an understanding of
#FDA Expedited Pathways for accelerating time-to-market for products treating serious conditions or unmet medical needs from Veristat#RegulatoryAffairs experts. Learn how. http://bit.ly/2rT7dtS pic.twitter.com/w4SawogcIz
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
When Do You Begin Planning Your Investigational New Drug Application (IND)? - Massachusetts Biotechnology Council http://bit.ly/2uivx9B pic.twitter.com/UNzQWNt7oR
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Veristat, LLC proslijedio/la je Tweet
In the pre-clinical stage of development, when should sponsors begin thinking about & planning for
#IND activities? Find out in our guest blog with@VeristatCRO: https://bit.ly/31hL3Pj pic.twitter.com/Uk30LnsO7R
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
View the on-demand webinar to learn about which considerations in your clinical trial database design may shorten or lengthen time-to-market. View now. http://bit.ly/37f0cmF pic.twitter.com/aixez4UTVA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Do you understand the benefits and qualifying criteria for six different
#FDA expedited programs and designations? Learn about Fast Track, Breakthrough Designation, QIDP, RMAT, and more. Get now. http://bit.ly/35imtOD pic.twitter.com/wArlm9oWnb
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Veristat, LLC proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Learn what new draft
#FDA Guidance was published and drafted in December 2019. Read Veristat's Regulatory Guidance Monthly Review for December 2019.#RegulatoryAffairs http://bit.ly/2QXxOOC pic.twitter.com/5WP3Mq8Ohr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Veristat, LLC proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Veristat, LLC proslijedio/la je Tweet
@VeristatCRO Congrats on the@ClinicalTrialCo acquisition Wishing you & your team much success in 2020Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Are you taking advantage of
#FDA Expedited programs that were designed to speed the availability of new therapies to patients with serious conditions or unmet medical needs? Learn more.#RegulatoryAffairs http://bit.ly/39x3gMn pic.twitter.com/KHaTIWCDZt
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Veristat, LLC proslijedio/la je Tweet
.
@VeristatCRO enhances European#clinicaltrials foothold, closing acquisition of@ClinicalTrialCo#CROs offer full-service support for global clinical studies; look to reveal synergies & new opportunities https://www.tctcgroup.com/#neurosciences#CellTherapy#pharma#biopharmapic.twitter.com/7t5cryRw4Q
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Veristat strengthens its European presence and expands therapeutic expertise with the acquisition of the TCTC Group. Read the press release for more details around our expanded capabilities: http://bit.ly/2SPcHAT pic.twitter.com/Q8u0sSMQCZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Is getting your product to market faster one of your new year’s resolutions? Consider using an expedited pathway to gain support for your development approach from
#FDA? View this infographic to learn about the types of expedited pathways. http://bit.ly/37yDAx7 pic.twitter.com/mmaIJSTQic
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Did you miss this exciting news over the holidays? Catalyst and Veristat join forces to create the most strategic team of regulatory experts to guide product development. Learn more now. http://bit.ly/2YRxDs1 pic.twitter.com/qB9CLrvqVE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Wishing you a year of success in 2020! We look forward to continuing to help our biopharmaceutical clients bring new therapies to market in the new year!pic.twitter.com/dzaYHjnbJr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Would having the most experienced regulatory team to develop and implement your regulatory strategy help fast track your clinical trials? Veristat has just amassed the premier
#regulatoryaffairs team to help. Learn more. http://bit.ly/2PWUoqu pic.twitter.com/B1QLnmgFLW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Veristat wishes you a Happy Holiday Season and a Happy New Year!
#ClinicalResearch http://bit.ly/2riupBs pic.twitter.com/oNyUf2C5MQ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Two like-minded teams of regulatory experts come together - Veristat and Catalyst Regulatory Services. Delivery of competent/proficient regulatory consulting, submissions and publishing solutions. Read how. http://bit.ly/2tomhju pic.twitter.com/XF9KoWJSip
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
You can improve
#clinicaltrials efficiency by selecting the right EDC system. Read the interview with Kathleen Boruchowski to learn how.#clinicaldatamanagment http://bit.ly/2Xu1dTN pic.twitter.com/JqSfzh4bEJ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Did you hear?
#CRO Veristat and Catalyst Regulatory Services have joined forces creating an unrivaled team of#regulatoryaffairs experts. Learn more. http://bit.ly/36GOQXC pic.twitter.com/NSsFrJbU4r
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
More here